A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
University of Miami
St. Jude Children's Research Hospital
National Institutes of Health Clinical Center (CC)
Tianjin Medical University Cancer Institute and Hospital
Sanofi
Merck Sharp & Dohme LLC
National Institutes of Health Clinical Center (CC)
University of Chicago
Mayo Clinic
Icahn School of Medicine at Mount Sinai
Hoffmann-La Roche
TerSera Therapeutics LLC
Hellenic Society of Hematology
Sanofi
M.D. Anderson Cancer Center
Oral Defense, LLC
M.D. Anderson Cancer Center
Janssen Research & Development, LLC
Stanford University
Stanford University
Eli Lilly and Company
M.D. Anderson Cancer Center
Duke University
National Institutes of Health Clinical Center (CC)